Study on the Relationship between sLOX-1, S100A12, D-dimer, and Cerebral Hemorrhage Transformation after Intravenous...

This study examines the relationship between serum biomarkers sLOX-1, S100A12, D-dimer and the risk of cerebral hemorrhage transformation following intravenous thrombolysis in stroke patients.

We retrospectively analyzed 161 stroke patients who underwent intravenous thrombolysis at our hospital from March 2021 to March 2023. Patients were categorized into hemorrhagic transformation (n=35) and non-hemorrhagic transformation groups (n=126) based on head CT scans conducted within 3 days post-treatment. We compared serum levels of sLOX-1, S100A12, and D-dimer between the groups and analyzed clinical data to evaluate factors influencing hemorrhagic transformation.

No significant differences were found in demographics, medical history, or stroke characteristics between the groups (P > .05). The hemorrhagic transformation group exhibited higher NIHSS scores, WBC levels, and lower UA levels (P < .05). Notably, sLOX-1, S100A12, and D-dimer levels were significantly elevated in the hemorrhagic group (P < .05). Multivariate regression and ROC curve analyses indicated these biomarkers and NIHSS scores significantly predict cerebral hemorrhage post-thrombolysis (P < .05).

Elevated sLOX-1, S100A12, and D-dimer levels are associated with an increased risk of cerebral hemorrhage transformation after thrombolysis in stroke patients. These biomarkers along with NIHSS and NIHSS scores, hold diagnostic value for predicting hemorrhagic outcomes.